The largest database of trusted experimental protocols

48 protocols using volasertib

1

LN229 Xenograft Tumor Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
LN229 cells (1 × 106) were injected subcutaneously into the dorsal flank of athymic BALB/c nude mice (4-week-old, female) from Jackson laboratory. Once the tumor volume reached 100 mm3, animals were divided into five subgroups: control 1 (TMZ vehicle), control 2 (volasertib vehicle), TMZ (Selleckchem, Cat: S1237) volasertib (Selleckchem, Cat: S2235), combination (TMZ + volasertib) (n = 3 mice). TMZ (25 mg/kg formulated in 10% DMSO in sterile PBS) and administrated intravenously every 3 days. TMZ (25 mg/kg formulated in 10% DMSO in sterile PBS) and administrated intravenously every 3 days. volasertib was formulated in hydrochloric acid (0.1 N) and diluted with 0.9% NaCl at 10 mg/kg concentration and delivered intravenously every 3 days. Each mouse’s tumor size was measured every 3 days after the first injection by a Vernier caliper. The volume of the tumor was calculated with the formula: volume = (length × width2)/2. In this case, 30 days after the injection, the mice were euthanized and the tumors were dissected for histological analysis.
+ Open protocol
+ Expand
2

Modulating Glioblastoma Stem Cells via PLK1 Inhibition

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD133+ U87 stem cells and CD133+ U251 stem cells were assigned to Blank group, control group, PLK1 inhibitor BI2536 group (treated with 0.5 nmol/L BI2536, Selleck Chemicals, Houston, TX), PLK1 inhibitor Volasertib group (treated with 0.5 nmol/L Volasertib, Selleck Chemicals), pcDNA3.1 group, pcDNA3.1‐PLK1 group (cells transfected with PLK1‐pcDNA3.1), si‐NC group, PLK1‐siRNA1 group (cells transfected with PLK1‐specific siRNA1) and PLK1‐siRNA2 group (cells transfected with PLK1‐specific siRNA2). The sequence of PLK1 siRNA is listed in Table 1. The oligonucleotides were purchased from Gene PharmaCo., Ltd. (Shanghai, China). U87 and U251 stem cells were plated in antibiotic‐free medium. Then, the medium was changed to serum‐free Opti‐MEM. Transfection was performed under the guidelines of Lipofectamine 2000 (Invitrogen Inc.).
+ Open protocol
+ Expand
3

Combinatorial Effects of Volasertib and Temozolomide on GBM Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Volasertib and temozolomide were purchased from Selleckchem, Houston, TX, USA. The cytotoxic effects of Volasertib (nM) (Selleckchem Cat: S2235) alone and with TMZ (µM) (Selleckchem Cat: S1237) in GBM cells were determined by MTT assay as described earlier [13 (link)]. A detailed method has been provided as a Supplementary Methodology. The combination index was calculated by CompuSyn software for drug combinations and general dose-effect analysis developed by Ting-Chao Chou, Memorial Sloan-Keltering Cancer Center, New York, NY, USA and Nick Martin Massachusetts Institute of Technology, Cambridge, MA, USA [14 (link)].
+ Open protocol
+ Expand
4

Molecular Mechanisms of Cell Cycle Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Imatinib, danusertib, volasertib and AZD1775 were purchased from Selleck Chemicals. For Western blotting, 10% acrylamide gels, running buffer (MOPS), transfer buffer and polyvinylidene difluoride (PVDF) transfer membrane were bought from Thermo Scientific. For immunofluorescence (IF), the FITC-conjugated anti-mouse IgG, the anti-rabbit conjugated with Alexa Fluor 568 antibodies and DAPI (6-diamidino-2-phenylindole) were purchased from Sigma-Aldrich.
The anti-cleaved-caspase 3 (Asp175), anti-cleaved-caspase 9 (Asp353), anti-BAX, anti-CHK1, anti-phospho-CHK1 (S317), anti-CHK2, anti-phospho-CHK2 (T68), anti-cyclin B1, anti-phospho-cyclin B1 (S133), anti CDC25C, anti-phospho-CDC25C (S198), anti-WEE1, anti-phospho-WEE1 (S642), anti-CDK1, anti-phospho-CDK1 (Y15), anti-phospho-H2AX (S139), anti-RAD51, anti- β-tubulin Alexa Fluor 555 Conjugate, anti-Aurora kinase A, anti-phospho-Aurora kinase A (T288), anti-PLK1, anti-phospho-PLK1 (T210), anti-PARP, anti-caspase-3 and anti-caspase-9 antibodies were purchased from Cell Signaling Technology. The anti-β-actin antibody used as loading control was purchased from Santa Cruz Biotechnology.
+ Open protocol
+ Expand
5

Dissecting PLK1 and E-cadherin Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-PLK1 (Invitrogen); anti-phosphorylated Myt1 (Thr495) and Myt1 (Thermo Fisher Scientific); anti-poly(ADP-ribose) polymerase, -cleaved poly(ADP-ribose) polymerase, -phosphorylated translational controlled tumor protein (TCTP; Ser46), -cyclin B1, -E-cadherin, -vimentin, -β-catenin, and -Snail (Cell Signaling Technology); anti-TCTP (Abcam); and anti-β-actin (Sigma) antibodies were used. The PLK1 inhibitors BI2536, volasertib, and GSK461364 were purchased from Selleck Chemicals and prepared as 10-mM stock solutions in dimethyl sulfoxide. Predesigned sets of 4 independent small interfering RNA (siRNA) sequences of the target genes PLK1 and CDH1 (siGENOME SMARTpool; Dharmacon) were used. Human transforming growth factor-β1 was purchased from Cell Signaling Technology.
+ Open protocol
+ Expand
6

Pharmacological Inhibitors in Cell Cycle Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
The pharmacological inhibitor thiostrepton was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Pharmacological inhibitors adavosertib, RO-3306, and volasertib (BI 6727) were purchased from Selleckchem (Houston, TX, USA). Pharmacological inhibitors aphidicolin and nocodazole were purchased from Cayman Chemical (Ann Arbor, MI, USA). Silencer Select siRNAs targeting FOXM1 (s5250), PLK1, Myt1 (s224087), Wee1 (s21), CDC25A (s2750), CDC25B (s2754), and CDC25C (s2758) and negative control, Lipofectamine RNAiMAX and Opti MEM were purchased from Thermo Fisher Scientific (Waltham, MA, USA). CDC2 siRNA (Cat # 3500S) was purchased from Cell Signaling Technologies (Danvers, MA, USA).
+ Open protocol
+ Expand
7

Evaluating PLK1 Inhibitor Cytotoxicity in SCLC

Check if the same lab product or an alternative is used in the 5 most similar protocols
PLK1 inhibitors Volasertib and BI2536 were obtained from SelleckChem. SCLC cells were seeded in 96-well plates at a density of 2.5 × 103 cells/well and incubated in a medium with threefold serial dilutions of PLK1 inhibitors, starting from 10 µM, for 72 h. After incubation with MTS reagent for 3 h, the absorbance was measured. Absorbance reading from the cells incubated without the inhibitor was used for 100% survival. Data were collected from six technical and three biological replicates for each cell line.
+ Open protocol
+ Expand
8

Multi-Drug Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Volasertib, BI2536, rigosertib, paclitaxel, zosuquidar and LY294002 were purchased from Selleck chemicals (Houston, TX), and poloxin was from Sigma-Aldrich (St.Louis, MO).
+ Open protocol
+ Expand
9

Pharmacological Cell Cycle Arrest and Release

Check if the same lab product or an alternative is used in the 5 most similar protocols
For pharmacological inhibition of PLK1, BI2536 (Selleckchem), BI6727 (Volasertib, Selleckchem), and poloxin (Selleckchem) were added to cells at the indicated final concentrations in growth medium. For inhibition of Aurora A kinase, Alisertib (MLN8237, Selleckchem) was added to cells at the indicated final concentrations in growth medium. Arrest of cells in S-phase and mitosis was achieved by supplementing growth medium with 3 µM aphidicolin (Sigma) or 330 nM nocodazole (Sigma), respectively, for 16 h. Arrest of cells at the G2/M boundary was achieved by growth medium with 9 µM RO-3306 (Selleckchem) for 20 h. Release from cell cycle arrest was performed by three washes with pre-heated (37 °C) growth medium.
+ Open protocol
+ Expand
10

Inhibitor Sensitivity in Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
PC9 (Sigma-Aldrich, Saint-Louis, MO, USA) and H1975 (ATCC, Manassas, VA, USA) cells were both cultured in RPMI-1640 medium (21875-034, Gibco, Waltham, MA, USA); HEK293T (ATCC) cells were cultured in DMEM (12491-015, Gibco). Both media were supplemented with 10% FBS (758093, Greiner, Monroe, NC, USA) and 1% penicillin-streptomycin. Cells were kept at 37 °C in a 5% CO2 atmosphere under sterile conditions. PLK1 and EGFR inhibitors were bought from Selleckchem (Houston, TX, USA): Volasertib (S2235), RO3280 (S7248), and Osimertinib (S7297). The final concentrations used are mentioned in the figure legends. Cycloheximide (C7698) was purchased from Sigma.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!